The Hidden Autoimmune Disease That Can Leave You Breathless and Weak

Waking up after a full night's sleep and still feeling completely wiped out not from a late night or a stressful week, but because your own immune system is quietly destroying your red blood cells faster than your body can replace them. That's the reality of warm autoimmune hemolytic anemia. In August 2026, the FDA approved IMAAVY (nipocalimab-aahu), the first treatment built specifically for this condition.

When Your Immune System Turns on Your Own Blood Cells

Your immune system is built to protect you. In wAIHA, it gets the target wrong, making antibodies that attach to red blood cells and help destroy them. As those cells break down, the body can't carry enough oxygen around. That leaves people feeling wiped out, weak, dizzy, pale, and short of breath. It's a rare condition, but it can turn serious quickly and needs proper medical management.

A New Medicine That Goes After the Actual Problem

IMAAVY works by bringing down the IgG antibodies in the bloodstream, including the ones attacking red blood cells. In plain terms, it strips away some of the "attack signals" driving the destruction. Steroids calm the whole immune system down broadly. IMAAVY goes after a specific part of the immune response instead. That targeted approach is a big part of why this approval matters.

What the Clinical Trial Actually Found

The Phase 2/3 ENERGY study ran across 115 adults with wAIHA and compared IMAAVY directly against placebo. At the approved dose, roughly three times as many patients held onto a lasting haemoglobin improvement by week 24. Patients on IMAAVY also saw an average haemoglobin rise of around 1 g/dL (gram per deciliter) by the end of the first week. Encouraging numbers, though how much any individual responds still varies from person to person.

Could This Actually Mean Less Exhaustion?

Potentially, but it's not a guaranteed overnight fix. Haemoglobin carries oxygen through the body, so lifting a low haemoglobin level can translate into real improvements in weakness and fatigue. Fatigue scores in the trial also improved with IMAAVY compared to placebo at 24 weeks. For someone who has spent months or years running on empty, even a meaningful shift in daily energy changes what life actually feels like.

What You Need to Know Before Starting

IMAAVY is approved for adults and adolescents aged 12 and older with wAIHA who are currently on or have previously used corticosteroids. It's given through an intravenous infusion and carries side effects including swelling, diarrhoea, and fever. It can raise infection risk and trigger allergic or infusion-related reactions, which is why careful monitoring by a haematologist isn't optional. This is not a medicine to start, stop, or switch to without proper medical guidance.

A New Option And a Real Reason for Hope

Living with a rare disease and running out of treatment options is its own kind of exhausting. IMAAVY doesn't cure wAIHA, and it won't work for everyone. But it gives doctors a targeted treatment they didn't have before and gives patients something worth having: another door that wasn't open until now.

If you have wAIHA or know someone living with it, speak with a haematologist about whether this treatment fits your situation. And if fatigue, breathlessness, or dizziness suddenly gets significantly worse, don't put it down to "just anaemia." Get it checked.